Drew M. Pardoll

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Molecular Biology, Immunology, Cell Biology
Google:
"Drew Pardoll"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hwang MS, Miller MS, Thirawatananond P, et al. (2021) Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. Nature Communications. 12: 5271
Berry S, Giraldo NA, Green BF, et al. (2021) Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science (New York, N.Y.). 372
Cheung LS, Chen L, Oke TF, et al. (2021) Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. Journal For Immunotherapy of Cancer. 9
Ligon JA, Choi W, Cojocaru G, et al. (2021) Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. Journal For Immunotherapy of Cancer. 9
Sidhom JW, Larman HB, Pardoll DM, et al. (2021) Author Correction: DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nature Communications. 12: 2309
Dykema AG, Zhang B, Woldemeskel BA, et al. (2021) Functional characterization of CD4+ T-cell receptors cross-reactive for SARS-CoV-2 and endemic coronaviruses. The Journal of Clinical Investigation
Hwang MS, Mog BJ, Douglass J, et al. (2021) Targeting loss of heterozygosity for cancer-specific immunotherapy. Proceedings of the National Academy of Sciences of the United States of America. 118
Sidhom JW, Larman HB, Pardoll DM, et al. (2021) DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nature Communications. 12: 1605
Alteber Z, Kotturi MF, Whelan S, et al. (2021) Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis. Cancer Discovery
Shenderov E, Boudadi K, Fu W, et al. (2021) Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial. The Prostate
See more...